利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

337 条记录 (耗时 0.051 秒)

    Compositions for inducing immune responses
    34.
    发明授权
    Compositions for inducing immune responses 有权
    用于诱导免疫反应的组合物

    公开(公告)号：US07731967B2

    公开(公告)日：2010-06-08

    申请号：US10837117

    申请日：2004-04-29

    申请人： Derek O'Hagan ,  Manmohan Singh

    发明人： Derek O'Hagan ,  Manmohan Singh

    IPC分类号： A61K39/00

    CPC分类号： A61K39/39 ,  A61K2039/55511 ,  A61K2039/55555

    摘要： The invention provides, inter alia, immunogenic compositions comprising a first antigen, at least two adjuvants, wherein a first adjuvant comprises a polymer derived from poly(lactides) and/or poly(lactide-co-glycolides), and wherein a second adjuvant comprises an imidazoquinoline, wherein said first antigen is encapsulated within, adsorbed or conjugated to, co-lyophilized or mixed with said first adjuvant, and a pharmaceutically acceptable excipient, wherein said composition elicits a cellular immune response when administered to a vertebrate subject. The invention also provides methods of producing immunogenic compositions, methods for producing a cytotoxic-T lymphocyte (CTL) response in a vertebrate subject, and methods of immunization.

    摘要翻译： 本发明尤其提供包含第一抗原，至少两种佐剂的免疫原性组合物，其中第一佐剂包含衍生自聚（丙交酯）和/或聚（丙交酯 - 共 - 乙交酯）的聚合物，并且其中第二佐剂包含 咪唑并喹啉，其中所述第一抗原包被在所述第一佐剂中并被共冻干或混合，吸附或缀合，以及药学上可接受的赋形剂，其中所述组合物在施用于脊椎动物受试者时引起细胞免疫应答。 本发明还提供产生免疫原性组合物的方法，在脊椎动物受试者中产生细胞毒性T淋巴细胞（CTL）应答的方法和免疫方法。

    Human FGF-21 gene and gene expression products
    35.
    发明授权
    Human FGF-21 gene and gene expression products 有权
    人FGF-21基因和基因表达产物

    公开(公告)号：US07723297B2

    公开(公告)日：2010-05-25

    申请号：US11405241

    申请日：2006-04-17

    申请人： Nobuyuki Itoh ,  Michael Kavanaugh

    发明人： Nobuyuki Itoh ,  Michael Kavanaugh

    IPC分类号： A61K38/18 ,  C07K14/475

    CPC分类号： G01N33/57407 ,  A61K38/00 ,  C07K14/50 ,  C12P21/02 ,  G01N33/57426 ,  G01N33/57438 ,  G01N33/576 ,  G01N33/6872 ,  G01N33/689 ,  G01N2333/50 ,  G01N2500/00 ,  G01N2800/085 ,  G01N2800/367

    摘要： This invention relates to human fibroblast growth factor (hFGF-21), and to variants thereof and to polynucleotides encoding FGF-21. The invention also relates to diagnostic and therapeutic agents related to the polynucleotides and proteins, including probes and antibodies, and to methods of treating liver disease such as cirrhosis and cancer, methods of treating conditions related to thymic function, and methods of treating conditions of the testis. The invention also relates to mouse fibroblast growth factor (mFGF-21), and to variants thereof and polynucleotides encoding mFGF-21.

    摘要翻译： 本发明涉及人成纤维细胞生长因子（hFGF-21）及其变体，以及编码FGF-21的多核苷酸。 本发明还涉及与多核苷酸和蛋白质相关的诊断和治疗剂，包括探针和抗体，以及治疗肝脏疾病如肝硬化和癌症的方法，治疗与胸腺功能相关的病症的方法，以及治疗 睾丸。 本发明还涉及小鼠成纤维细胞生长因子（mFGF-21）及其变体和编码mFGF-21的多核苷酸。

    Treatment of severe pneumonia by administration of tissue factor pathway inhibitor (TFPI)
    36.
    发明授权
    Treatment of severe pneumonia by administration of tissue factor pathway inhibitor (TFPI) 失效
    通过给予组织因子途径抑制剂（TFPI）治疗重症肺炎

    公开(公告)号：US07674769B2

    公开(公告)日：2010-03-09

    申请号：US10270478

    申请日：2002-10-15

    申请人： Abla Creasey

    发明人： Abla Creasey

    IPC分类号： A61K38/57 ,  C07K14/81

    CPC分类号： B82Y10/00 ,  A61K38/57 ,  A61K2039/505 ,  A61K2300/00

    摘要： Methods for prophylactically or therapeutically treating severe pneumonia involve administration of tissue factor pathway inhibitor (TFPI) or a TFPI analog to patients suffering from or at risk of developing this condition. The methods involve the use of continuous intravenous infusion of TFPI or a TFPI analog, preferably at low doses to avoid adverse side effects.

    摘要翻译： 用于预防或治疗重症肺炎的方法涉及组织因子途径抑制剂（TFPI）或TFPI类似物给患有或有发展该病症风险的患者。 所述方法包括使用连续静脉内输注TFPI或TFPI类似物，优选低剂量以避免不良副作用。

    Pancreatic cancer genes
    38.
    发明授权
    Pancreatic cancer genes 失效
    胰腺癌基因

    公开(公告)号：US07666992B2

    公开(公告)日：2010-02-23

    申请号：US11929813

    申请日：2007-10-30

    申请人： Giulia Kennedy

    发明人： Giulia Kennedy

    IPC分类号： C07K1/00 ,  A61K38/04 ,  C12P21/04 ,  C12P21/06 ,  C07H21/04

    CPC分类号： C07K14/47

    摘要： The present invention provides the art with the DNA coding sequences of polynucleotides that are up-or-down-regulated in cancer and dysplasia. These polynucleotides and encoded proteins or polypeptides can be used in the diagnosis or identification of cancer and dysplasia. Inhibitors of the up-regulated polynucleotides and proteins can decrease the abnormality of cancer and dysplasia. Enhancing the expression of down-regulated polynucleotides or introducing down-regulated proteins to cells can decrease the growth and/or abnormal characteristics of cancer and dysplasia.

    摘要翻译： 本发明提供了在癌症和发育不良中上下调的多核苷酸的DNA编码序列的技术。 这些多核苷酸和编码的蛋白质或多肽可用于诊断或鉴定癌症和发育不良。 上调多核苷酸和蛋白质的抑制剂可以减少癌症和发育异常的异常。 增强下调多核苷酸的表达或将下调蛋白引入细胞可以降低癌症和发育不良的生长和/或异常特征。

    Method for using lipoprotein associated coagulation inhibitor to treat sepsis
    40.
    发明授权
    Method for using lipoprotein associated coagulation inhibitor to treat sepsis 失效
    使用脂蛋白​​相关凝血抑制剂治疗败血症的方法

    公开(公告)号：US07662774B2

    公开(公告)日：2010-02-16

    申请号：US10891493

    申请日：2004-07-15

    申请人： Abla A. Creasey ,  George J. Broze

    发明人： Abla A. Creasey ,  George J. Broze

    IPC分类号： C07K14/00

    CPC分类号： A61K38/57 ,  C07K14/8114 ,  Y02A50/473

    摘要： A method for prophylactically or therapeutically treating sepsis or septic shock is described, wherein an inhibitor to tissue factor is administered to septic patients. Additionally, a method for treating inflammation is described wherein the inhibitor is administered to patients. This inhibitor is termed lipoprotein associated coagulation inhibitor, or commonly LACI. It is 38 kD and has 276 amino acids. LACI has now been shown to be useful for the treatment of sepsis, septic shock and inflammation.

    摘要翻译： 描述了一种用于预防或治疗性治疗败血症或败血性休克的方法，其中向败血症患者施用组织因子抑制剂。 另外，描述了治疗炎症的方法，其中将抑制剂施用于患者。 该抑制剂称为脂蛋白相关的凝血抑制剂，或通常为LACI。 它是38 kD，有276个氨基酸。 LACI已被证明可用于治疗败血症，败血性休克和炎症。